Skip to main content
. 2013 Mar 27;5(3):120–126. doi: 10.4254/wjh.v5.i3.120

Table 1.

Characteristics of the studies included in the systematic analysis

Ref. Study design No. of patients Age (yr) Weight HCV genotype Baseline treatment history Child-Pugh class Treatment
Syed et al[12] Retrospective cohort study 104 52 ± 7.6 82 ± 15 kg (mean weight) 1, 2, 3 Naive and previously treated A Pegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1-1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Butt et al[13] Prospective cohort study 66 46.2 ± 10.1 22.3 ± 3.1 kg/m² (mean BMI) 3 Naive and previously treated A, B Pegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Giannini et al[14] Retrospective cohort study 85 56 ± 9 Not specified 1, 2, 3, 4 Naive and previously treated A, B Pegylated interferon alpha 2a (180 μg/wk) or alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/ d)
Helbling et al[15] Randomized controlled trial (standard doses vs low doses) 64 47 (median age) 74 kg (median weight) 1, 2, 3, 4 Naive A Pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/ d)
Iacobellis et al[16] Prospective cohort study 94 Not specified Not specified 1, 2, 3, 4 Naive B Pegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Roffi et al[17] Randomized controlled trial (pegylated interferon vs IFN standard) 57 56 (median age) 75 kg (median weight) 1, 2, 3 Naive A Pegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800-1200 mg/d)
Sood et al[18] Retrospective cohort study 28 48.3 ± 7 73.9 ± 11.2 kg (mean weight) 3 (25/28 patients) and not specified for the other patients Naive A, B Pegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (10-12 mg/kg per day)
Tekin et al[19] Cohort study 20 54.2 ± 5.9 Not specified 1 Not specified A, B Pegylated interferon alpha 2a (135 μg/wk)
Ribavirin (1000-1200 mg/d)
Moreno Planas et al[20] Cohort study 12 52 ± 8 Not specified 1, 3 Naive and previously treated A, B Pegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (10.6 mg/kg per day)
Di Marco et al[21] Randomized controlled trial (pegylated interferon alpha 2B + ribavirin vs pegylated interferon alpha 2b) 52 57 ± 6.6 71 ± 10.1 kg (mean weight) 1, 2, 3, 4 Naive and previously treated A, B Pegylated interferon alpha 2b (1 μg/kg per week)
Ribavirin (800 mg/d)
Höroldt et al[22] Retrospective cohort study 61 Not specified Not specified 1, 2, 3 Naive A, B Pegylated interferon alpha 2a or alpha 2b + ribavirin
Bruno et al[23] Randomized study 106 Not specified Not specified 1, 2, 3, 4 Naive A Pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Floreani et al[24] Prospective cohort study 87 55.7 ± 9.1 25.3 ± 3.1 kg/m² (mean BMI) 1, 2, 3 Naive A Pegylated interferon alpha 2b (80-100 μg/wk)
Ribavirin (1000-1200 mg/d)
Annicchiarico et al[25] Prospective cohort study 15 51.5 Not specified 1, 2, 3 Naive and previously treated B, C Pegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (800-1200 mg/d)
Aghemo et al[26] Prospective cohort study 106 57 ± 9.3 72.5 ± 11.8 kg (mean weight) 1, 2, 3, 4 Naive A Pegylated interferon alpha 2b (1.5 μg/kg per week)
Ribavirin (≥ 10.6 mg/kg per day)
Kim et al[27] Cohort study 86 56.4 ± 9.6 Not specified 1 and non-1 Not specified A Pegylated interferon alpha 2b (1.5 μg/kg per week)
or Pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)
Reiberger et al[28] Prospective cohort study 90 51 ± 8 26.6 ± 5 kg/m² (mean BMI) 1, 2, 3, 4 Not specified A Pegylated interferon alpha 2b (1.5 μg/kg per week)
or pegylated interferon alpha 2a (180 μg/wk)
Ribavirin (1000-1200 mg/d)

HCV: Hepatitis C virus; BMI: Body mass index; IFN: Interferon.